Overall rank by patents
#45,443
of 49,997 tracked assignees
USPTO PatentsView assignee record - 5 granted patents across 2 technology areas, recorded in grant years 2021–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).
The verdict
According to USPTO PatentsView, Cancer ranks #45,443 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 2 technology areas.
USPTO PatentsView assignee plate
Corpus R45443 · US Corporation #45,443 · 5 grants
GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · SPAN-YRS · BOOK-RICH
Nearest grant-volume peer: Campagnie Generale Des Etablissements Michelin (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
Cancer Prevention… · this assignee
29 score
3D Lighting… · lowest
7 score
What this shows Cancer's Innovation Score is 29.3/100 (30th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
Cancer Prevention Pharmaceuticals, Inc. is a focused PatentsView assignee: 2 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (2 grants) versus a trough of 1 in 2022. By volume, Cancer sits between Campagnie Generale Des Etablissements Michelin and Canna-Chemistries LLC.
Cancer Prevention Pharmaceuticals, Inc. shows 2 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Campagnie Generale Des Etablissements Michelin
5 patents
CanSemi Technology Inc.
5 patents
CanWell Biotech Limited
5 patents
Canada Goose Inc.
5 patents
Candesant Biomedical, Inc.
5 patents
Cane Creek Cycling Components, Inc.
5 patents
Cangrade, Inc.
5 patents
Canna-Chemistries LLC
5 patents
Cancer Prevention Pharmaceuticals, Inc.
5 patents
What this shows Cancer holds 5 patents at rank #45,730, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #45,730 in granted patent volume.
Other assignees with the most granted patents in Cancer's primary technology class.
Cancer's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
29 30th percentile higher than 30% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2021–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2021 | 2 | 40.0% |
| 2022 | 1 | 20.0% |
| 2024 | 1 | 20.0% |
| 2025partial year | 1 | 20.0% |
Top 2 of 2 technology areas
Overall rank by patents
#45,443
of 49,997 tracked assignees
29.3 out of 100
What to do with this data
Cancer Prevention Pharmaceuticals, Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.